|
|
| Line 114: |
Line 114: |
|
| |
|
|
| |
|
| <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
| |
| ==Immunophenotype== | | ==Immunophenotype== |
|
| |
|
|
| |
|
| Typical FL has CD10+, BL2+. Atypical FL subgroups CD10- and/or BCL2 - all FL are STMN+ - useful differentiator between atypical FL and MZL [9]
| | Typically, FL is CD10+, BL2+. Atypical FL subgroups CD10- and/or BCL2 - all FL are STMN+ - useful differentiator between atypical FL and MZL [9] |
|
| |
|
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| Line 134: |
Line 133: |
|
| |
|
|
| |
|
| <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 9, 10]</blockquote>
| |
| ==Chromosomal Rearrangements (Gene Fusions)== | | ==Chromosomal Rearrangements (Gene Fusions)== |
|
| |
|
| Put your text here and fill in the table
| | <br /> |
|
| |
|
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| Line 147: |
Line 145: |
| !Notes | | !Notes |
| |- | | |- |
| |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC) | | |t(14;18)(q32;q21)||5' IGH / 3' BCL2||der(18)||80%~90% |
| EXAMPLE 30% (add reference)
| |
| |Yes
| |
| |No | | |No |
| |Yes | | |No |
| |EXAMPLE | | |No |
| | | |Rarely, BCL2 rearrangement may also be observed with IGK at 2p11.2 or IGL at 22q11.22. |
| The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
| |
| |} | | |} |
| | | |
